Loading patent…
AssigneesGoliver Therapeutics, Nantes Universite, Institut National de la Sante et de la Recherche Medicale
InventorsTuan Huy Nguyen, Angélique Fourrier, Raphaël Rispal, Frédéric Delbos
Estimating the term…
The present invention relates to a population of cells comprising hepatic stem-like cells and therapeutic use thereof, for the treatment and the prevention of fulminant liver disorders. The hepatic stem-like cells according to the invention may be safely and reproducibly generated from pluripotent stem cells. In addition, although the hepatic stem-like cells according to the invention do not display the phenotype of physiologically mature hepatic cells, as they are lacking the albumin expression marker (ALB−), they may still be transplanted in a diseased liver with acute failure, rescue the diseased liver and promote liver regeneration. Moreover, various protocols of preparation of hepatic stem-like cells according to the invention may be implemented, all resulting in high quality and high yield of production. Finally, the hepatic stem-like cells according to the invention may be cryopreserved and may also be prepared as spheroid particles.
An isolated population of cells, comprising at least 5% of hepatic stem-like cells expressing the alpha-fœtoprotein marker (AFP+) and not expressing the albumin marker (ALB−), or an extract thereof.
(canceled)
Dependencies are inferred from the claim text.